(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Getting through a Lifelong Change: Individual Examples of overcoming adversity - 2The secret appeal of Harlan Coben’s messy, addictive TV thrillers
- 3Public Parks in the USA
- 4Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- 5All the eclipses, supermoons, meteor showers and planets to spot in 2026
- Watch SpaceX launch NASA's Pandora exoplanet-studying satellite on Jan. 11
- 6 Exemplary Mexican Dishes
- See tonight’s solar storm unfold across the world
- Supreme Court case about ‘crisis pregnancy centers’ highlights debate over truthful advertising standards
- 41 Young Men Die in South Africa After Circumcision Initiation
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
- Protester climbs on to balcony of Iranian embassy in London
- Find Exemplary Scents: An Extensive Aide
- Thousands of ultra-orthodox protest in Jerusalem against conscription
